About Tonix Pharmaceuticals Holding Corp.
In the Phase 2 PREVAIL trial in fibromyalgia-type Long COVID, bedtime TNX-102 SL resulted in a signal in fatigue, sleep and cognitive ...
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia New Drug ...
The firm’s stock price fluctuated 11.05% within the last five trades and 18.75% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the ...
TNXP stock results show that Tonix Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for ...
DelveInsight's Binge Eating Disorder Market Insights report includes a comprehensive understanding of current treatment ...
17d
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with ...
Cocaine Use Disorder market Forecast. DelveInsight's Cocaine Use Disorder Market report offers an in-depth understanding of the epidemiology and market tre ...
The growth of the binge eating disorder market is expected to be mainly driven by increasing prevalence, advancements in diagnosis, the launch of emerging therapies, and an upsurge in the geriatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results